Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2012

View Archived Issues

Abbott presents new serotonin 5-HT6 receptor modulators

Co-clinical study method identifies mutations limiting lung cancer treatment efficacy

Tyrosine-protein kinase SYK inhibitor has beneficial effects on asthma

Preliminary phase I results presented on AZD-2014

Olodaterol shows efficacy in asthma trials

Clinical data show long-term effects of lebrikizumab and the role of periostin

Novel GPR17 receptor modulators reported by Italian group

Theravance discloses novel candidate hepatitis C therapies

GlaxoSmithKline discovers new LDH-A inhibitors

Novel treatments for IBD prepared by Spanish team

Researchers at Marine Polymer Technologies patent new potential melanoma vaccines

Astellas and Drais partner on another IBS drug candidate

OTSA-101 receives E.U. orphan drug status

GE Healthcare and Affibody collaborate on HER2-specific PET imaging agent

Baxter and Chatham enter collaboration on hemophilia B gene therapy development

Takeda expands its position in gout market

First-in-human data presented on novel selective Notch pathway inhibitor

AFFiRiS launches first-ever clinical study of vaccine candidate for Parkinson's disease

Cleveland BioLabs reports survival results with CBLB-502

Emergent BioSolutions obtains BARDA funding for BioThrax

Evotec/Boehringer Ingelheim alliance reaches milestone

ThromboGenics and BioInvent to regain global rights to PlGF-directed mAb

Phase IIb data on anticoagulant lead to decision to stop its development

Genmab and Novartis enter bispecific antibody collaboration

Dainippon Sumitomo Pharma and Shionogi to copromote combination hypertension drug in Japan

Janssen files NDA for canagliflozin

Astellas and Ambit begin phase IIb quizartinib monotherapy study in relapsed/refractory AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...